Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cel-Sci, a cancer drug development company, has expanded its exclusive licensing agreement for Multikine with Orient Europharma, a Taiwan-based pharmaceutical company.
Subscribe to our email newsletter
The new agreement extends the Multikine collaboration to also cover South Korea, the Philippines, Australia and New Zealand. The licensing agreement initially focuses on the areas of head and neck cancer, nasopharyngeal cancer and potentially cervical cancer.
As part of this new agreement, Orient Europharma will invest $500,000 in Cel-Sci and fund a portion of the company’s global Phase III clinical trial for Multikine due to start in 2009. Orient Europharma’s clinical group will conduct part of the clinical study in its territory.
In addition to making a direct investment in the company and funding a portion of the clinical trials, Orient Europharma will also be responsible for registering the product in the territory. Once Multikine has been approved, Cel-Sci will be responsible for manufacturing the product, while Orient Europharma will be responsible for sales in the territory. Revenues will be split between Cel-Sci and Orient Europharma.
Geert Kersten, CEO of Cel-Sci, said: “We are pleased that Orient Europharma has recognized the potential for Multikine and has extended its license into more countries.”